Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ: RGNX )

7.300 -0.020 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 700,891
Open 7.250
Bid (Size) 7.300 (2)
Ask (Size) 7.730 (1)
Prev. Close 7.320
Today's Range 7.230 - 7.760
52wk Range 6.560 - 28.80
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases. 
Via Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts
Via Benzinga

Performance

YTD
-7.12%
-7.12%
1 Month
+2.10%
+2.10%
3 Month
-28.08%
-28.08%
6 Month
-41.51%
-41.51%
1 Year
-61.23%
-61.23%

More News

Read More
Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Where Regenxbio Stands With Analysts
Via Benzinga
5 Analysts Have This To Say About Regenxbio
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
Workday, Apollo Global To Join S&P 500 Index In Quarterly Balance
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
What's Going On With REGENXBIO Shares Monday?
Via Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Assessing Regenxbio: Insights From 5 Financial Analysts
Via Benzinga
Where Regenxbio Stands With Analysts
Via Benzinga
Assessing Regenxbio: Insights From 4 Financial Analysts
Via Benzinga
Evaluating Regenxbio: Insights From 9 Financial Analysts
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
Via FinancialNewsMedia
Exposures COVID-19
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
Why Is Clearside Biomedical Stock Gaining Today?
Via Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Via Benzinga
Exposures Product Safety
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
Via Investor's Business Daily
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Via Investor's Business Daily
Exposures Product Safety
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.